153 related articles for article (PubMed ID: 34337682)
1. The integrative bioinformatic analysis deciphers the predicted molecular target gene and pathway from curcumin derivative CCA-1.1 against triple-negative breast cancer (TNBC).
Novitasari D; Jenie RI; Kato JY; Meiyanto E
J Egypt Natl Canc Inst; 2021 Aug; 33(1):19. PubMed ID: 34337682
[TBL] [Abstract][Full Text] [Related]
2. Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis.
Ma J; Chen C; Liu S; Ji J; Wu D; Huang P; Wei D; Fan Z; Ren L
Cancer Gene Ther; 2022 Nov; 29(11):1578-1589. PubMed ID: 35474355
[TBL] [Abstract][Full Text] [Related]
3. Network Pharmacology and Experimental Validation to Explore the Effect and Mechanism of Kanglaite Injection Against Triple-Negative Breast Cancer.
Zhao M; Fu L; Xu P; Wang T; Li P
Drug Des Devel Ther; 2023; 17():901-917. PubMed ID: 36998242
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of CCNE1 confers a poorer prognosis in triple-negative breast cancer identified by bioinformatic analysis.
Yuan Q; Zheng L; Liao Y; Wu G
World J Surg Oncol; 2021 Mar; 19(1):86. PubMed ID: 33757543
[TBL] [Abstract][Full Text] [Related]
5. Hsa-mir-3163 and CCNB1 may be potential biomarkers and therapeutic targets for androgen receptor positive triple-negative breast cancer.
Qiu P; Guo Q; Yao Q; Chen J; Lin J
PLoS One; 2021; 16(11):e0254283. PubMed ID: 34797837
[TBL] [Abstract][Full Text] [Related]
6. Integrated network analysis and machine learning approach for the identification of key genes of triple-negative breast cancer.
Naorem LD; Muthaiyan M; Venkatesan A
J Cell Biochem; 2019 Apr; 120(4):6154-6167. PubMed ID: 30302816
[TBL] [Abstract][Full Text] [Related]
7. KEGG-expressed genes and pathways in triple negative breast cancer: Protocol for a systematic review and data mining.
Chen J; Liu C; Cen J; Liang T; Xue J; Zeng H; Zhang Z; Xu G; Yu C; Lu Z; Wang Z; Jiang J; Zhan X; Zeng J
Medicine (Baltimore); 2020 May; 99(18):e19986. PubMed ID: 32358373
[TBL] [Abstract][Full Text] [Related]
8. The Growth Suppression Activity of Diosmin and PGV-1 Co-Treatment on 4T1 Breast Cancer Targets Mitotic Regulatory Proteins.
Musyayyadah H; Wulandari F; Nangimi AF; Anggraeni AD; Ikawati M; Meiyanto E
Asian Pac J Cancer Prev; 2021 Sep; 22(9):2929-2938. PubMed ID: 34582664
[TBL] [Abstract][Full Text] [Related]
9. Identification of Key Prognostic Genes of Triple Negative Breast Cancer by LASSO-Based Machine Learning and Bioinformatics Analysis.
Chen DL; Cai JH; Wang CCN
Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627287
[TBL] [Abstract][Full Text] [Related]
10. Upregulated cyclins may be novel genes for triple-negative breast cancer based on bioinformatic analysis.
Lu Y; Yang G; Xiao Y; Zhang T; Su F; Chang R; Ling X; Bai Y
Breast Cancer; 2020 Sep; 27(5):903-911. PubMed ID: 32338339
[TBL] [Abstract][Full Text] [Related]
11. Novel biomarkers identified in triple-negative breast cancer through RNA-sequencing.
Chen YL; Wang K; Xie F; Zhuo ZL; Liu C; Yang Y; Wang S; Zhao XT
Clin Chim Acta; 2022 Jun; 531():302-308. PubMed ID: 35504321
[TBL] [Abstract][Full Text] [Related]
12. Identification of key genes as potential biomarkers for triple‑negative breast cancer using integrating genomics analysis.
Zhong G; Lou W; Shen Q; Yu K; Zheng Y
Mol Med Rep; 2020 Feb; 21(2):557-566. PubMed ID: 31974598
[TBL] [Abstract][Full Text] [Related]
13. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis.
Zhai Q; Li H; Sun L; Yuan Y; Wang X
Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620
[TBL] [Abstract][Full Text] [Related]
14. [Bioinformatic analysis of direct protein targets of aspirin against human breast cancer proliferation].
Zhu X; Yang J; Zhang E; Qiao W; Li X
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Oct; 39(10):1141-1148. PubMed ID: 31801720
[TBL] [Abstract][Full Text] [Related]
15. Integrated analysis of differentially expressed genes and pathways in triple‑negative breast cancer.
Peng C; Ma W; Xia W; Zheng W
Mol Med Rep; 2017 Mar; 15(3):1087-1094. PubMed ID: 28075450
[TBL] [Abstract][Full Text] [Related]
16. Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis.
He J; Yang J; Chen W; Wu H; Yuan Z; Wang K; Li G; Sun J; Yu L
PLoS One; 2015; 10(6):e0129842. PubMed ID: 26103053
[TBL] [Abstract][Full Text] [Related]
17. Selected ideal natural ligand against TNBC by inhibiting CDC20, using bioinformatics and molecular biology.
Liu N; Wang X; Zhu Z; Li D; Lv X; Chen Y; Xie H; Guo Z; Song D
Aging (Albany NY); 2021 Oct; 13(20):23702-23725. PubMed ID: 34686627
[TBL] [Abstract][Full Text] [Related]
18. Exploration of the Pharmacological Mechanism of Vitexicarpin against Triple-Negative Breast Cancer in Network Pharmacology.
Wu T; Xiang M; Li Y; Gao Y; Teng D; Sun M; Guo W; Zhou Y
Front Biosci (Landmark Ed); 2023 Dec; 28(12):341. PubMed ID: 38179762
[TBL] [Abstract][Full Text] [Related]
19. Virtual screening of the multi-gene regulatory molecular mechanism of Si-Wu-tang against non-triple-negative breast cancer based on network pharmacology combined with experimental validation.
Zhang Z; Liu J; Liu Y; Shi D; He Y; Zhao P
J Ethnopharmacol; 2021 Apr; 269():113696. PubMed ID: 33358854
[TBL] [Abstract][Full Text] [Related]
20. Screening and Identification of Key Biomarkers in Inflammatory Breast Cancer Through Integrated Bioinformatic Analyses.
Wu J; Lv Q; Huang H; Zhu M; Meng D
Genet Test Mol Biomarkers; 2020 Aug; 24(8):484-491. PubMed ID: 32598242
[No Abstract] [Full Text] [Related]
[Next] [New Search]
